Press Releases Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-29 pm EDT			5-day change	1st Jan Change
5.94 ^USD	+1.19%		+10.61%	-2.14%

Apr. 24	Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	MT
Apr. 24	Amneal Pharmaceuticals Shares Rise 9% After FDA Approves Naloxone Spray	DJ

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

California is joining with a New Jersey company to buy a generic opioid overdose reversal drug	Apr. 29	AQ
Amneal Announces U.S. FDA Approval of Over-the-Counter Naloxone Hydrochloride Nasal Spray for Emergency Treatment of an Opioid Overdose	Apr. 24	BU
Amneal Launches PEMRYDI RTU, the First Ready-to-Use Version of Important Oncology Injectable Medicine	Apr. 17	AQ
Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine	Apr. 16	BU
Amneal to Report First Quarter 2024 Results on May 3, 2024	Apr. 10	BU
Amneal to Ring the Nasdaq Closing Bell on April 2, 2024	Mar. 28	BU
Amneal Pharmaceuticals, LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful	Mar. 28	AQ
Amneal Pharmaceuticals : LLC. Issues a Nationwide Voluntary Recall of Vancomycin Hydrochloride for Oral Solution USP, 250mg/5mL, due to the potential for some bottles to be super potent which may be harmful.	Mar. 27	PU
Amneal Receives U.S. FDA Approval for Ciprofloxacin and Dexamethasone Otic Suspension	Mar. 25	BU
Amneal Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 04	AQ
Amneal: Q4 Earnings Snapshot	Mar. 01	AQ
Amneal Reports Fourth Quarter and Full Year 2023 Financial Results	Mar. 01	BU
Amneal Enters into Exclusive European Licensing Agreement with Zambon Biotech for IPX203	Feb. 27	BU
Amneal to Participate at Upcoming Investor Conference	Feb. 13	BU
Amneal Announces Complete Response Resubmission for IPX203 New Drug Application	Feb. 08	AQ
Amneal to Report Fourth Quarter and Full Year 2023 Results on March 1, 2024	Jan. 31	BU
Amneal Launches Complex Generic Fluorometholone Ophthalmic Suspension	Jan. 10	BU
Amneal Launched Record Number of 39 New Retail and Injectable Products in 2023, Including 13 in Q4 2023	Jan. 04	BU
Amneal to Participate at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 21	BU
Amneal Announces Move to Nasdaq	Dec. 18	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Amneal Pharmaceuticals, Inc.

Equities

AMRX

US03168L1052

Press Releases

Filters